Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. 68Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET/CT and 123I-MIBG SPECT/CT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. 18F-labeled norepinephrine transporter tracer [18F]NS12137: radiosynthesis and preclinical evaluation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Synthesis and evaluation of (18)F-labeled 5-HT2A receptor agonists as PET ligands

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Automated synthesis and PET evaluation of both enantiomers of [¹⁸F]FMISO

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Changes in cardiac microvascular function in persons with type 2 diabetes in relation to kidney function

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

Vis graf over relationer
Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.
OriginalsprogEngelsk
TidsskriftNuclear Medicine and Biology
Vol/bind40
Udgave nummer5
Sider (fra-til)618-24
Antal sider7
ISSN0969-8051
DOI
StatusUdgivet - jul. 2013

ID: 43160130